CTIF

Across TCGA pan-cancer cohorts, CTIF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CTIF data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CTIF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CTIF expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where CTIF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.737	0.999	.003	44	view →
LUAD	DFS	Tertile	All	0.744	0.454	.008	12	view →
CCRCC	DFS	Median	All	0.849	0.981	.007	11	view →
PDAC	OS	Quartile	All	0.502	0.725	.025	8	view →
HNSC	OS	Median	All	0.620	0.797	.011	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CTIF–LSCC (DFS)

Open the LSCC breakdown →